Avience Biomedicals shareholders and shareholding pattern
NSE: AVIENCEHealthcare Equipment & Supplies
Avience Biomedicals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 2026 · Issue price ₹208
Last close ₹264.95down ₹5.75 (2.12%)
Share price at the NSE close on 29 Oct 2026. Previous close ₹270.70.
29 Oct: open ₹272.00, high ₹272.00, low ₹263.55
Range of traded prices from listing on 25 Jun 2026 to 29 Oct 2026
₹222.00Low, 17 Jul 2026₹414.95High, 25 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹145 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 16.60
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in Jun 2026
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 27.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.92
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 10,20070.6% delivered
Avience Biomedicals' shareholding pattern for Sep 2026, filed on 19 Oct 2026: who owns its shares by group, its promoters by name and its public holders of 1% or more.
Who owns Avience Biomedicals, filing by filing
Per cent of the company's shares.
Sep 2026 filing
- Promoters64.59%
- Foreign institutions0.03%
- Indian institutions3.48%
- Individuals and others31.89%
| Per cent | Sep 2026 |
|---|---|
| 64.59% | |
| Indian promoters | 64.59% |
| Public. Every shareholder outside the promoter group, the employee trusts and the shares held against depositary receipts, as the filing totals them. Public in the glossary | 35.41% |
| Shares in issue | 54,85,056 |
| Shares locked inShares locked in. Shares the filing reports as barred from sale until a set day, such as promoters' shares after a public issue or shares allotted to an investor directly. Shares locked in in the glossary | 40,31,256 |
| Promoters' shares locked in | 35,42,885 |
A dash is a line the filing did not state.
Avience Biomedicals promoters
Promoters are the founders, families and companies that control the company, as its filings name them. Every member of the promoter group holding shares in the filing for Sep 2026; the largest is DHARM DEO CHOUDHARY, 37.17%. The filing names 22 more members with no shares.
| Holder | |||
|---|---|---|---|
| DHARM DEO CHOUDHARYIndividuals and Hindu undivided families | 37.17% | 20,38,756 | 100.00% |
| RAM NAGINA CHOUDHARYIndividuals and Hindu undivided families | 11.71% | 6,42,370 | 100.00% |
| DEEPA CHOUDHARYIndividuals and Hindu undivided families | 7.99% | 4,38,400 | 100.00% |
| JANARDAN PALIndividuals and Hindu undivided families | 7.66% | 4,20,359 | 100.00% |
| GEETA CHOUDHARYIndividuals and Hindu undivided families | 0.02% | 1,000 | 100.00% |
| ARTI PALIndividuals and Hindu undivided families | 0.02% | 1,000 | 100.00% |
| KAPIL DEO CHOUDHARYIndividuals and Hindu undivided families | 0.02% | 1,000 | 100.00% |
No promoter shares are reported as pledged. Locked in is the share of the holder's own shares that cannot be sold yet, as after a listing or an allotment.
Largest public holders of Avience Biomedicals, filing by filing
Per cent, on the same shares as the split above.
| Holder | Sep 2026 |
|---|---|
| MANIRAMKA COMPOUND 365 LLPCompanies | 3.65% |
| SANDEEP KUMAR HISARIAResident individuals, over ₹2 lakh at face value | 1.82% |
| FORTUNE HANDS GROWTH FUND- FORTUNE HANDS GROWTH FUND SCHEMEAlternative investment funds | 1.32% |
| A.T. TRADE OVERSEAS PRIVATE LIMITEDCompanies | 1.31% |
| GINNI FINANCE PRIVATE LIMITEDCompanies | 1.05% |
| ASNANI STOCK BROKER PRIVATE LIMITEDCompanies | 1.02% |
A filing names every holder above one per cent, in the company's own words: an insurer's holding can carry one of its funds' names. A dash is a filing that did not name the holder, which includes holding under one per cent.
Who moved in the Sep 2026 filing
Against the Jun 2026 filing. A filing names a public holder only at 1% or more, so a holder no longer named fell under 1% or sold out.
- Foreign institutions: MERU INVESTMENT FUND PCC-CELL 1 no longer named, from 2.20%
- Indian institutions: SANSHI FUND-I no longer named, from 2.64%; FORTUNE HANDS GROWTH FUND- FORTUNE HANDS GROWTH FUND SCHEME 1.32%, −0.43 pts
- Individuals and others: SANDEEP KUMAR HISARIA newly named at 1.82%; A.T. TRADE OVERSEAS PRIVATE LIMITED newly named at 1.31%; GINNI FINANCE PRIVATE LIMITED newly named at 1.05%; 1 more moved